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Introduction: Autologous blood-derived biologicals, including autologous conditioned serum (ACS), are frequently used
to treat tendinopathies in horses despite limited evidence for their efficacy. The purpose of this study was to describe the
effect of a single intralesional injection of ACS in naturally occurring tendinopathies of the equine superficial digital flexor
tendon (SDFT) on clinical, ultrasonographic, and histological parameters.
Methods: Fifteen horses with 17 naturally occurring tendinopathies of forelimb SDFTs were examined clinically and
ultrasonographically (day 0). Injured tendons were randomly assigned to the ACS-treated group (n = 10) receiving a single
intralesional ACS injection or included as controls (n = 7) which were either untreated or injected with saline on day 1. All
horses participated in a gradually increasing exercise programme and were re-examined nine times at regular intervals
until day 190. Needle biopsies were taken from the SDFTs on days 0, 36 and 190 and examined
histologically and for the expression of collagen types I and III by immunohistochemistry.
Results: In ACS-treated limbs lameness decreased significantly until day 10 after treatment. Swelling (scores) of the SDFT
region decreased within the ACS group between 50 and 78 days after treatment. Ultrasonographically, the percentage of
the lesion in the tendon was significantly lower and the echogenicity of the lesion (total echo score) was significantly
higher 78 and 106 days after intralesional ACS injection compared to controls. Histology revealed that, compared to
controls, tenocyte nuclei were more spindle-shaped 36 days after ACS injection. Immunohistochemistry showed that
collagen type I expression significantly increased between days 36 and 190 after ACS injection.
Conclusions: Single intralesional ACS injection of equine SDFTs with clinical signs of acute tendinopathy contributes to
an early significant reduction of lameness and leads to temporary improvement of ultrasonographic parameters of repair
tissue. Intralesional ACS treatment might decrease proliferation of tenocytes 5 weeks after treatment and increase their
differentiation as demonstrated by elevated collagen type I expression in the remodelling phase. Potential enhancement
of these effects by repeated injections should be tested in future controlled clinical investigations.
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Tendinopathy of the superficial digital flexor tendon
(SDFT) is a common injury in Thoroughbred racehorses
and other horse breeds and is regarded as a career-
limiting disease with a high recurrence rate [1]. Numerous
treatment modalities have shown limited success in im-
proving tendon repair [2]. Regenerative therapy aims to* Correspondence: florian.geburek@tiho-hannover.de
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creativecommons.org/publicdomain/zero/1.0/restore structure and function after application of biocom-
patible materials, cells, and bioactive molecules [3, 4].
There is growing knowledge about the clinical effects of
potentially regenerative substrates, e.g. mesenchymal stem
cells (MSCs) [5, 6] and autologous blood products such as
platelet rich plasma [7, 8] on equine tendinopathies. To
date, however, ideal treatment strategies for naturally oc-
curring tendinopathies have not been established [1, 2].
Autologous conditioned serum (ACS; synonyms irapW,
OrthokineW, Orthogen, Düsseldorf, Germany) is used for
intralesional treatment of tendinopathy in horses but, toarticle distributed under the terms of the Creative Commons Attribution License
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mented anecdotally [8–10]. ACS is prepared by exposing
whole blood samples to glass beads, which has been shown
to stimulate the secretion of anti-inflammatory cyto-
kines, including interleukin (IL)-4 and IL-10 and IL-1
receptor antagonist (IL-1Ra) in humans [11]. A recent
investigation has shown that ACS from equine blood
also contains high levels of IL-1Ra and IL-10 [12].
Equine studies have focused on the IL-1Ra-mediated
anti-inflammatory effects of ACS [13]; however, in tendon
healing, the high concentrations of growth factors such as
insulin-like growth factor-1 (IGF-1) and transforming
growth factor-beta (TGF-β) may be equally or more
important [14–16]. Blood samples from different horses
and the use of different kits for the preparation of ACS
may lead to differences in the cytokine and growth factor
concentration in vitro [12, 17]. However, the relevance of
these differences for the clinical effect is unknown.
ACS was originally described to improve muscle re-
generation in a murine muscle contusion model [18]
and to exhibit anti-inflammatory effects in an experi-
mental model of carpal osteoarthritis in horses [13] and
in a placebo-controlled clinical trial in humans with
knee osteoarthritis [19].
The rationale for the use of ACS to treat equine tendino-
pathies is based on several findings: 1) It was shown in an
experimental study that the expression of IL-1β (and matrix
metalloproteinase-13) is upregulated following overstrain in-
jury of rat tendons, demonstrating that these molecules are
important mediators in the pathogenesis of tendinopathy
[15, 20]. 2) IL-1Ra protein and heterologous conditioned
serum prepared with the irapW kit reduced the production
of prostaglandin E2 by stimulated cells derived from macro-
scopically normal SDFTs in vitro [21]. 3) Growth factors
concentrated in ACS, e.g. IGF-1 and TGF-β, have the po-
tential to attract resident precursor cells, e.g. MSCs
and tenoblasts, and to increase cell proliferation dur-
ing tendon healing [14, 15, 17]. Rat Achilles tendons
exposed to ACS in an experimental study showed an
enhanced expression of the Col1A1 gene, which led to
an increased secretion of type I collagen and acceler-
ated recovery of tendon stiffness and improved histo-
logic maturity of the repair tissue [22]. It was shown in
another rodent Achilles tendon transection model that
ACS generally increases the expression of basic fibro-
blast growth factor (bFGF), bone morphogenetic protein-
12 and TGF-β1 [16], representing growth factors import-
ant for the process of tendon regeneration [15].
The process of tendon healing is mainly divided into
three phases which merge into each other. The acute in-
flammatory phase (<10–14 days) is characterized by
phagocytosis and demarcation of injured tendon tissue.
A fibroproliferative callus is formed during the prolifera-
tive phase (4–45 days), while collagen fibrils are organisedinto tendon bundles during the remodelling or maturation
phase (45–120 days; <3 months) [1, 23].
The aim of the present study was to support the hypoth-
esis that a single intralesional ACS injection into SDFT le-
sions 1) has a clinically detectable anti-inflammatory
effect, 2) leads to improved B-mode ultrasonographic
parameters and 3) improves the organization of repair
tissue.
Materials and methods
Inclusion criteria for client-owned adult horses was a
history of acute uni- or bilateral SDFT tendinopathy
(tendon disorder) without cutaneous injury but with
clinical signs of inflammation being reported to be
present for up to 14 days prior to the presentation at the
Equine Clinic of the University of Veterinary Medicine,
Hannover, Foundation, or to collaborating veterinarians.
Horses were only included if the clients agreed to the
study design and tendons had not received intralesional
injections before. Injured limbs were randomly assigned
to the group treated with ACS (n = 10) or to controls
(n = 7). The study was carried out between 2009 and
2012 and approved by the animal welfare officer of the
University of Veterinary Medicine Hannover, Foundation,
Germany, and the ethics committee of the responsible
German federal state authority in accordance with the
German Animal Welfare Law (Lower Saxony State
Office for Consumer Protection and Food Safety, Az.
33.9-42502-05-09A652).
Clinical examination
All horses were examined clinically on the day of first
presentation (day 0). This examination included visual
assessment of lameness (5 grade score) [24] and signs of
inflammation which were scored semiquantitatively by
palpation (skin surface temperature in the palmar meta-
carpal region and sensitivity of the SDFT to palpation: 0
= no abnormality, 1 = mild abnormality, 2 = moderate
abnormality, and 3 = severe abnormality; swelling of the
SDFT was determined by palpation as an increase in
diameter relative to normal tendon: 0 = no increase, 1 =
increase by factor 1.5; 2 = increase by factor 1.5 to 2; in-
crease by more than factor 2 [25]).
B-mode ultrasonography
All injured tendons were examined with B-mode ultra-
sound on the day of first presentation (day 0) in a trans-
verse and longitudinal fashion with a linear 5–7.5 MHz
linear scanner (Logiq e, GE Healthcare, Wauwatosa, WI,
USA), according to the seven zone designations as de-
scribed previously [26, 27]. Images were stored digitally
and analysed according to the following parameters to
determine the degree- and time-related changes of the
lesions: maximal injury zone (MIZ), type of lesion
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lesion = centrally located, focal hypo-/anechoic region;
marginal lesion = peripherally located, focal hypo-/
anechoic region; diffuse lesion = homogenous or
heterogenous changes in echogenicity of the whole/
most parts of the cross sectional area), summarized
cross-sectional areas of the tendon (total cross-sectional
area, T-CSA), summarized cross-sectional areas of the le-
sion (total lesion cross-sectional area, TL-CSA), and per-
centage of the lesion in the tendon [percent total lesion,
%T-lesion = (TL-CSA / T-CSA) × 100]. Echogenicity and
fibre alignment were graded semiquantitatively at each
zone and the scores for all levels were summarized (total
echo score, TES; total fibre alignment score, T-FAS).
Echogenicity was assigned to 0 (normoechoic), 1 (hypoe-
choic), 2 (mixed echogenicity), and 3 (anechoic) [27, 28],
and fibre alignment was graded according to the estimated
percentage of parallel fibres in the lesion: 0 (>75 %), 1
(50–74 %), 2 (25–49 %), and 3 (<25 %) [27, 28]. Analyses
of ultrasonograms were performed by one examiner (ML)
blinded to the individual treatment modality.
Intralesional treatment, follow-up examinations and
controlled exercise
Ten millilitres of autologous blood were collected by a
single venipuncture of one jugular vein into an irapW-10
syringe system (Orthogen, Düsseldorf, Germany). Blood
samples were incubated at 37 °C (range 6–9 hours).
After centrifugation at 4,000 rotations per minute for
10 minutes (centrifuge: Universal 320, rotor: no. 1624,
Hettich, Tuttlingen, Germany), serum was aseptically
aspirated from the syringe and passed through a 0.22
μm syringe-driven filter unit (Millex-MP, Millipore
Corporation, Carrigtwohill, Co. Cork, Ireland). Depending
on the size of the lesion as determined ultrasonographi-
cally (TL-CSA), tendons allocated to the ACS group re-
ceived a single intralesional injection of 1–3 ml through a
22G needle (diameter 0.7 mm, length 30 mm) into the
SDFT defect (day 1). Control tendons either received a
single injection of a placebo, i.e. 1–3 ml saline through a
22G needle (diameter 0.7 mm, length 30 mm) or were
untreated in case the owner declined an intralesional
application of saline. Horses were sedated for the intra-
lesional injections with detomidine (0.01–0.03 mg/kg
intravenously) and butorphanol (0.04–0.05 mg/kg intra-
venously), and the medial and lateral palmar nerves
were anaesthetized 2 cm distal to the carpometacarpal
joints with 2 ml of a 2 % mepivacaine solution. After
aseptic preparation of the skin, superficial digital tendon
lesions were injected under sonographic guidance at a
single site from the lateral aspect of the tendon perpen-
dicularly to its long axis directly into the most hypoechoic
areas, i.e. the MIZ while the limb was weight-bearing. All
horses participated in a gradually increasing exerciseprogramme as described previously [7]. The programme
started the first day after the reported onset of SDFT
tendinopathy. From week 25 to 27 horses were exercised
for 25 minutes at a walk and for 15 minutes at a trot.
Horses were re-examined clinically and ultrasonogra-
phically at regular intervals for 27 weeks on days 11, 22,
36, 50, 78, 106, 134, 162, and 190. Thereafter horse
owners were advised to gradually increase exercise on an
individual basis until the previous level of performance
was reached. Data concerning signs of acute tendon in-
jury, the level of performance horses reached and the
discipline they were used for were obtained by telephone
inquiry with horse owners or trainers until the prepar-
ation of the manuscript.
Needle biopsies and histologic examinations
On days 0, 36 and 190, one needle biopsy was taken
aseptically from each SDFT at its MIZ with a 20G auto-
mated biopsy needle (Biopsiepistole PlusSpeed™, Peter
Pflugbeil GmbH, Zorneding, Germany), with the needle
entering the MIZ of the SDFT from distal at a 45° angle
while the carpus was flexed approximately 90° and the
metacarpophalangeal joint was moderately extended
[29]. Pain reaction and intensity of bleeding from the bi-
opsy site were evaluated using an established score [29].
The MIZ was recorded as distance from the accessory
carpal bone (cm) so that repeat biopsies were taken from
the same anatomic area as the day 0 biopsy while avoid-
ing previous biopsy sites. Limbs were protected with a
distal limb bandage for 2 days after taking needle biop-
sies and after intralesional injections. All needle biopsies
were fixed in 10 % formalin, paraffin-embedded, sectioned
at a thickness of 1–2 μm, mounted on microscope slides,
and stained with haematoxylin and eosin. A single histo-
logical slide of each biopsy was examined histologically ac-
cording to a score described previously [7, 30]; findings
were graded using a semiquantitative four-point scale (0 =
normal appearance, 1 = slightly abnormal, 2 = moderately
abnormal, and 3 = markedly abnormal) considering the
following parameters: fibre structure (0 = linear, no inter-
ruption; 3 = short with early truncuation), fibre alignment
(0 = regularly ordered; 3 = no pattern identified), morph-
ology of tenocyte nuclei (0 = flat; 3 = round), variations in
cell density (0 = uniform; 3 = high regional variation), and
vascularisation (0 = absent; 3 = high). Histological sections
were independently scored by two observers blinded to
horse and treatment modality (FG and ML). In total, five
high power fields (40× magnification) per section were ex-
amined and scored. Mean averages of score values deter-
mined by each observer were calculated for each
parameter (see above) before score values of both exam-
iners were averaged.
Immunohistochemical analysis of paraffin-embedded
tissue sections was used to determine the formation of
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available mouse-anti-bovine antibody (NB600-450 anti-
COL 1A1, Novus Biologicals, Littleton, CO, USA) and a
rabbit-anti-bovine antibody (CL197P anti collagen type
III alpha 1 chain, Acris Antibodies GmbH, Herford,
Germany) were applied as primary antibodies against
collagen type I and collagen type III, respectively. Sec-
ondary biotinylated antibodies were obtained from rele-
vant species allowing binding to the primary antibody.
Colour production from the chromogen diaminobenzi-
dine tetrachloride was catalysed by streptavidin-
conjugated peroxidase (avidin-biotin-complex-method)
[31]. Finally, the sections were counterstained with
haematoxylin. Immunohistochemical cross-reactivity of
antibodies with uninjured equine tendon tissue was
tested prior to analysis of the needle biopsies. Positive
control tissues included bovine aorta and bovine tendon
for collagen type I antigen-specific antibodies and bo-
vine skin for collagen type III antigen-specific anti-
bodies. In negative control sections, primary antibodies
were replaced by appropriately diluted Balb/c mouse as-
cites and rabbit serum, respectively.
Photomicrographs were taken from all immunostained
slides (Color View II, 3.3 Megapixel CCD, Soft Imaging
System GmbH, Münster, Germany). Quantitative mor-
phometric analysis of the immunoreaction was achieved
by determination of the immunostained area using
image analysis software (analySISW 3.1, Soft Imaging
System GmbH, Münster, Germany). A threshold for a
positive signal was defined and the percentage of posi-
tively immunostained area in the tissue section as a
whole was calculated [32, 33].Statistical analysis
Analysis of data was performed using SAS™ Version 9.3
(SAS Institute, Cary, NC, USA). The level of significance
was set at p < 0.05. All values in the graphs are expressed
as arithmetic mean values with standard error (X ± SEM).
The assumption of normality was tested using the
Kolmogorov-Smirnov test and visual assessment of qq-
plots of model residuals. In the case of rejection of normal
distribution, distribution-free nonparametric methods
were applied. Fisher’s exact test was applied to test the
differences between groups on each examination day
with regard to the parameters of degree of lameness,
swelling and skin surface temperature. To compare
not-normally distributed parameters within a group
between examination days, the permutation test for
nonparametric analysis of repeated measurements with
the Šidák post hoc test for multiple pairwise compari-
sons was used. The influence of groups and time points
on ultrasonongraphic parameters (T-CSA, TL-CSA,
%T-lesion, TES and T-FAS), histology scores andpercentages of positively immunostained areas were
tested using a two-way analysis of variance for inde-
pendent samples (groups) and repeated measurements
(dependent time points, biopsies), followed by the
Tukey post hoc test for multiple pairwise comparisons.
The intraclass correlation coefficient was calculated by
analysis of variance components to test inter-observer
repeatability of histological scores.
Results
Description and history of horses, intralesional injections
Seventeen limbs of 15 horses between 2 and 19 years old
(mean 8.46 years old) met the inclusion criteria. Ten of
the limbs were included in the ACS-treated group (ACS
group) and seven served as controls. Limbs allocated to
the ACS group belonged to five Warmbloods (50 %),
four Thoroughbreds (40 %) and one Arabian (10 %). The
limbs of five Warmbloods (71.42 %), one Thoroughbred
(14.28 %) and one Half-blood (14.28 %) were included as
controls. Of these, one Thoroughbred and one Warm-
blood with bilateral SDFT lesions served for both groups
(Table 1). The horses’ history (i.e. high-speed exercise,
increased age >12 years) was suggestive of tendinopathy
to be strain-induced in at least 6 of 10 SDFTs (60 %) al-
located to the ACS group and in at least 4 of 7 (57 %)
control SDFTs. Two tendons had a definitive history of
blunt external trauma. One was included in the ACS
group and one served as control.
In total ten SDFTs were injected with ACS. Five con-
trol SDFTs were not treated and two control tendons re-
ceived a single intralesional injection of saline.
Lameness
On day 0, the mean degree of lameness was 0.8 in the
ACS group. In control limbs, the mean degree of lameness
was 1.42 on day 0. One of the two horses with bilateral
tendinopathy that served for the ACS group and as a con-
trol was not lame. The second one showed a unilateral
front limb lameness (SDFT in the lame limb was treated
with ACS). The mean degree of lameness did not differ
between groups on any day of examination (p > 0.05).
Regardless of treatment modality all horses became
sound by day 36. Compared to day 0, lameness decreased
significantly by day 11 (p = 0.046) within the ACS group
and it decreased significantly by day 36 (p = 0.021) in
limbs serving as controls (Fig. 1a).
Long-term follow-up
Recurrence of tendon injury was not reported in any horse
after 2 to 4 years post-diagnosis. Of the eight horses with
SDFTs being allocated to the ACS group, five horses (63
%), among these three racehorses, returned to their pre-
vious or a higher performance level, two horses (25 %)
died of reasons unrelated to tendinopathy, and one






















2241/09 Thoroughbred 2 S Racing 2 Training RF 2b Diffuse ACS
2240/09 Thoroughbred 3 S Racing 2–3 Training RF 2b Core ACS
2489/09a Thoroughbred 4 M Racing 7 Racing RF 1b Core ACS
2539/09 Warmblood 3 S Dressage 14 Blunt trauma RF 2b Marginal ACS
1672/10 Arabian 17 G Pleasure 14 Running free RF 1b Core ACS
6264/10b Warmblood 8 G Dressage 9 Unknown RF 3a Marginal ACS
6335/10 Warmblood 10 G Pleasure 10 Unknown LF 2b Diffuse ACS
4793/10 Thoroughbred 3 S Racing 7 Training LF 2b Core ACS
6263/10 Warmblood 20 M Pleasure 14 Stumbling at cross
country ride
RF 1b Core ACS




2489/09a Thoroughbred 4 M Racing 7 Racing LF 1b Diffuse No
6264/10b Warmblood 8 G Dressage 9 Unknown LF 2a Core Saline
6111/10 Warmblood 5 M Jumping 14 Kicking himself over
the jump
RF 1b Marginal No
6265/10 Warmblood 5 M Pleasure 7 Unknown RF 1b Marginal Saline
6383/11 Warmblood 18 M Pleasure 10 At cross country
ride
LF 2a Marginal No
5461/11 Warmblood 14 G Police horse 4 At gallop on beach LF 2b Diffuse No
6384/11 Half-blood 8 G Eventing 1 After eventing
competition
LF 2a Core No
Mean
8.86
a, bHorses had bilateral SDFT lesions and served for the ACS group and as control. ACS autologous conditioned serum (treated with single intralesional injection of
autologous conditioned serum); G gelding, LF left front limb, M mare, RF right front limb, S stallion, Saline treated with single intralesional saline injection,
SDFT superficial digital flexor tendon
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phalangeal joints after the observation period. One of
the horses which was included in the ACS group and
served as a control did not resume training and was re-
tired as a broodmare; the second one performed as a
dressage horse. Of the five horses with tendons serving
only as control, four individuals (80 %) performed in
their discipline at the previous or a higher level, and one
horse (20 %) was lost to follow-up.
Signs of inflammation
No statistically significant differences between groups
were observed during the entire observation period, in-
cluding day 0, with regard to scores for swelling, skin
surface temperature and sensitivity to palpation. Swelling
scores of the SDFT region decreased significantly in the
ACS group (p = 0.005) between day 50 (mean score 1.1)and day 78 (mean score 0.7) and remained reduced until
the end of the observation period (Fig. 1b). In controls,
swelling scores did not decrease significantly during 27
weeks. Skin surface temperature and sensitivity to palpa-
tion scores decreased up to day 22 within both groups
and remained at a low level until day 190.
B-mode ultrasonography
The horses included presented with core lesions (seven
limbs), marginal lesions (five limbs) or diffuse lesions
(five limbs) of the SDFT (Table 1). The MIZ of most le-
sions was located in zone 2b (41.17 % of limbs), followed
by zone 1b (35.29 % of limbs), zone 2a (17.64 % of limbs)
and zone 3a (5.88 % of limbs).
The mean %T-lesion was 21.73 ± 7.16 in the ACS
group and 18.51 ± 5.07 in controls on day 0. This par-
ameter was significantly lower (p < 0.05) in the ACS
Fig. 1 Degree of lameness and palpable swelling of tendons. a Degree of lameness of control limbs and those treated with autologous
conditioned serum (ACS) over time. b Scores for palpable swelling of ACS-treated and control superficial digital flexor tendons (SDFTs) over time.
Mean ± SE. Different letters (ACS normal, and control italic) indicate significant differences (p < 0.05) within treatment group. ACS-group, n = 10
limbs (SDFTs treated with a single injection of ACS); controls, n = 7 limbs (SDFTs treated with a single injection of control substance or left
untreated). Black arrow day (d)0 – diagnosis, first tendon biopsy; red arrow d1 – intralesional injection of ACS/control substance; blue arrows
d36/d190 – second/third tendon biopsy
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TES were significantly lower in the ACS group versus
controls on days 78 and 106 (Fig. 2b). There was no dif-
ference in T-CSA, TL-CSA (Fig. 2c) or T-FAS between
the groups at any time point.
Mean %T-lesion showed a continuous decrease over
time within the ACS group which was significant (p =
0.02) for the first time on day 78 compared to day 0.
After this period, this parameter remained below the 10
% range. In control tendons, mean %T-lesion continu-
ously remained on a similar elevated level (p > 0.05)
throughout the entire observation period (Fig. 2a).
Compared to day 0, the mean TES decreased signifi-
cantly on day 22 and again between days 22 and 78 inthe ACS group (p < 0.05), while in controls compared to
day 0 the TES decreased significantly (p < 0.05) the first
time on day 78 (Fig. 2b).
Mean T-CSA did not change significantly throughout
the observation period in either group. Regarding the
progression of TL-CSA within the ACS group over time,
it was significantly lower (p < 0.05) from day 78 onwards
until the end of the examination period compared to
levels on day 0, while values from control tendons
remained on a similar level from day 0 to 190 (Fig. 2c).
Mean T-FAS decreased significantly between day 0 and
day 78 (p = 0.023) within the ACS group; in controls this
parameter decreased significantly on day 134 compared
to day 0 (p = 0.04).
Fig. 2 (See legend on next page.)
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Fig. 2 Ultrasonographic measurements. a Percent total lesion (%T-Lesion) of autologous conditioned serum (ACS)-treated and control superficial
digital flexor tendons (SDFTs) over time. b Total echo scores of ACS-treated and control SDFTs over time. c Total lesion cross-sectional area
(TL-CSA) of ACS-treated and control SDFTs over time. Mean ± SE. *p < 0.05, between groups. Different letters (ACS normal, and control italic)
indicate significant differences (p < 0.05) within treatment group. ACS-group, n = 10 limbs (SDFTs treated with a single injection of ACS); controls,
n = 7 limbs (SDFTs treated with a single injection of control substance or left untreated). Black arrow day (d)0 – diagnosis, first tendon biopsy; red
arrow d1 – intralesional injection of ACS/control substance; blue arrows d36/d190 – second/third tendon biopsy
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A total of 51 needle biopsies were taken. Pain reaction
was mild in 78.43 % of the procedures, mild to moderate
in 17.64 % and moderate in 3.92 % of the cases. A mod-
erate to severe or severe pain reaction was not observed.
No bleeding was observed after taking biopsies in 25.49
% of the cases, mild bleeding occurred in 58.82 % and
moderate bleeding in 15.68 % of cases. Severe bleeding
was not observed.
Of 51 biopsies, 47 were available for tendon histology
[7, 30]. Four biopsies from severely oedematous lesions
were not evaluated due to limited tissue content. The
intra-class correlation for inter-observer repeatability
was 0.72 for fibre structure, 0.88 for fibre alignment,
0.84 for nuclei morphology and 0.92 for variations in cell
density.
Scores for tenocyte nuclei morphology were signifi-
cantly lower (i.e. cell nuclei more flattened; p = 0.01) in
the ACS group (Fig. 3a) than in controls (Fig. 3b) on day
36 (Fig. 4a). Scores for cell density showed a tendency to
be lower (i.e. more uniform) in the ACS group than in
controls on day 36 (p = 0.052). Scores for fibre structure,
fibre alignment (Fig. 4b), vascularisation, and subscores
for structural integrity and metabolic activity did not
show differences between the ACS group and controls at
any time point.
With regard to development of fibre alignment during
the healing of tendons treated with ACS, scores for this
parameter were significantly lower (i.e. fibres were more
regularly ordered; p = 0.04) in biopsies taken at the end
of the observation period (day 190; Fig. 3d, Fig. 4b) than
in those taken on day 0 (Fig. 3c, Fig. 4b). In control ten-
dons, scores for fibre alignment (Fig. 4b), scores for
morphology of tenocyte nuclei (Fig. 4a) and scores for cell
density decreased significantly (i.e. tissue morphology im-
proved; p < 0.05) between day 36 and day 190 biopsies.
There were no differences between the ACS group and
controls with regard to collagen type I and collagen type
III expression in biopsies taken on days 0, 36 and 190.
Within the ACS group, the collagen type I content
increased significantly (p = 0.03) between the biopsies
taken on day 36 (Fig. 3e) and day 190 (Fig. 3f ), while it
remained at the same level (p > 0.05) in controls
(Fig. 4c). The collagen type III content showed a ten-
dency (p = 0.056) to decrease in the ACS group between
samples taken on days 0 and 190.Discussion
Results of the present study show that a single intrale-
sional ACS injection into SDFT lesions leads to a tem-
porary improvement of ultrasonographic parameters
[27, 28]. Transient flattened morphology of tenocyte
nuclei and an increased collagen type I expression in
ACS-treated tendons over time are indicative of reduced
proliferation and increased differentiation of this cell
type, respectively [1, 34, 35]. The therapeutic effect of
ACS treatment is also demonstrated by an earlier
decrease in lameness as compared to controls [2].
The history of the horses was suggestive of strain-
induced tendinopathy in the majority of tendons treated
with either modality. However, it remains unclear
whether the effects shown in the current study equally
apply to tendinopathies related to other etiologies. Al-
though the reported duration of tendinopathy of up to 2
weeks before first examination (day 0) referred to clin-
ical signs in the present study, subclinical degeneration
is known to precede obvious clinical symptoms of
strain-induced tendinopathies, especially in equine ath-
letes [36]. It cannot be excluded that at least some of the
tendons on day 0 were not in the inflammatory, but in
the early proliferative phase of tendon healing, although
neither B-mode ultrasonography nor histology yielded
clear evidence of potential chronicity of the tendinopa-
thies. As an alternative, either more extensive tendon bi-
opsies or ultrasonographic tissue characterization as a
noninvasive diagnostic tool could have been used ini-
tially to further determine the age of the lesions [37, 38].
As tendon composition and biomechanical properties
may vary significantly between horses [39] intraindivi-
dual controls (control = contralateral limb) are preferred
in experimental settings [7]. For these reasons, both
front limbs of two horses showing clinical signs of bilat-
eral SDFT tendinopathy were included in the ACS group
and as controls. Unfortunately, this could not be realised
in more horses. Only two out of five clients who agreed
to their horse or the respective limb being included as a
control accepted an intralesional injection of these con-
trol tendons. Thus, the objective to create two separate
control groups, one with the lesion left untreated and
one with an intralesional saline injection, could not be
achieved. Treatment modalities of control groups in
clinical and experimental trials may be seen controver-
sially. On the one hand, it is of interest to compare the
Fig. 3 Longitudinal sections of tendon biopsies from superficial digital flexor tendons with tendinopathy. a–d Histopathological specimens
stained with haematoxylin & eosin using a 40× objective. Tendons of horses on day 36 after intralesional treatment with autologous conditioned
serum (ACS) (horse no. 4793/10; a) and no treatment (control tendon, horse no. 6384/11; b). The number of round cell nuclei was higher in
control tendons than in ACS-treated tendons 36 days after treatment. Scale bars = 10 μm. Tendon of horse no. 2241/09 1 day before (day 0, c)
and 190 days after (d) intralesional treatment with ACS. Alignment of collagen fibres improved significantly between day 0 and day 190 after ACS
treatment. Scale bars = 10 μm. Tendon of horse no. 2240/09 36 days (e) and 190 days (f) after intralesional treatment with ACS. Immunohisto-
chemistry revealed a significant increase of collagen type I expression between day 36 and day 190 after ACS treatment. Scale bars = 20 μm
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strate injected intralesionally with the effect of con-
trolled exercise alone (= argument against intralesional
injection of a control substance into control tendons).
On the other hand, the mere puncture and needle decom-
pression of acute tendon defects may have a therapeutic ef-
fect independent of the substrate injected [2]. Against that
background, it seems preferable to treat control tendons
with sham injections to demonstrate the effect of the sub-
strate injected [5, 7] (ACS in the present case).
Tendon biopsies were used because clinical assessment
of tendon healing and B-mode ultrasonography alone
are limited with regard to sensitivity and reproducibility
[40] and longitudinal needle biopsies were established in
human [41, 42] and equine surgery [29, 43] as minimally
invasive and well-tolerated techniques. They allow aninsight into tendon architecture as well as the immunohis-
tochemical detection of, for example, collagen type I and
III [44]. Disadvantages, however, are the potentially thera-
peutic, albeit unknown, effect of the biopsy process on ten-
don healing [2, 45], their limited reproducibility and the
relatively small volume of tendon tissue harvested [29, 43].
Although mean degree of lameness did not differ be-
tween groups, this does not necessarily imply similar
functional repair of the lesions, since SDFTs are gener-
ally more exposed to maximal load during heavy
athletic activities than during trot, i.e. later during re-
habilitation [46]. The observation that, compared to
day 0, a significant decrease in lameness occurred earl-
ier in the ACS group, i.e. until day 11, compared to the
controls (day 36) may be influenced by effects attrib-
uted to ACS [8, 11, 13].
Fig. 4 Histologic scores and collagen type I content of superficial digital flexor tendons. a Histologic scores for morphology of tenocyte nuclei in
tendon biopsies taken from autologous conditioned serum (ACS)-treated versus control superficial digital flexor tendons (SDFTs) at different time
points during the examination period of 190 days. b Histologic scores for fibre alignment in tendon biopsies taken from ACS-treated versus control
SDFTs at different time points during the examination period of 190 days. c Percentage of collagen type I content determined immunohistochemically
in tendon biopsies taken from ACS-treated versus control SDFTs at different time points during the examination period of 190 days. Day (d)0 = day
the diagnosis was made; d36/d190 = 36/190 days after tendinopathy was diagnosed. *p < 0.05. ACS group, n = 10 limbs (SDFTs treated with a single
injection of ACS); controls, n = 7 limbs (SDFTs treated with a single injection of control substance or left untreated)
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lesions may be more challenging than detection of unilat-
eral gait abnormality [47]. It cannot be excluded that the
two horses with bilateral SDFT tendinopathy may have
shown bilateral lameness or an additional contralaterallameness, respectively, if diagnostic analgesia had been
performed.
Clinical signs of inflammation were monitored using
semiquantitative clinical score systems which may be
subject to some inaccuracy. This could have been improved
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and measurements of the metacarpal circumference in
combination with ultrasonography [49]. None of the in-
flammatory signs, including swelling, differed between
groups, but palpable swelling decreased significantly within
the ACS group between days 50 and 78 in contrast to con-
trols. On the one hand this may be attributed to auto- and
paracrine effects of ACS on endogenous growth factor ex-
pression, since in a rodent Achilles tendon transection
model bFGF expression was enhanced but not before 8
weeks, i.e. delayed after ACS injection [16]. On the other
hand controlled exercise exerted anti-inflammatory effects
on tendons from both groups [50] which did not, however,
lead to a significant decrease in swelling in controls.
The decrease of palpable swelling in the ACS group
between days 50 and 78 correlates positively with the
ultrasonographic finding that TL-CSA and %T-lesion de-
creased only in the ACS group between before treatment
and day 78. T-CSA, however, remained unchanged
throughout the entire observation period in both groups.
This proves that the decrease in swelling in the ACS
group rather reflects a decrease in cutaneous, subcutane-
ous and peritendinous swelling than an altered tendon
thickness in the late proliferation and early remodelling
phase (i.e. until around day 45). This may be due to a
therapeutic effect of inadvertent reflux of small volumes
of ACS into the subcutis during intralesional injection.
Ultrasonographic measurements of extratendinous swell-
ing are challenging and were not included in the present
study, although they could have been helpful to further
confirm findings of palpation. In contrast to the results of
this study, rat Achilles tendons showed an increase in ten-
don thickness after ACS treatment compared to the con-
trol tendons [22]. However, comparability is limited since
the rat tendons, in contrast to the present study, were su-
tured and received three treatments of ACS.
The present study shows that, compared to control
tendons, a single intralesional injection of ACS leads to
a significant reduction of %T-lesion and an increase in
echogenicity (TES) 78 and 106 days after treatment. This
finding corresponds to an earlier (until day 22) increase
in TES and an earlier (until day 78) increase of the per-
centage in parallel orientated fibre bundles (T-FAS) in
the ACS group compared to controls. These effects
could be the result of stimulation of repair tissue, i.e. im-
proved fibrillogenesis in the early proliferative phase of
tendon healing (4–45 days after injury) [23, 28, 37] in
which most horses were presented and treated. This
may have been a consequence of the potential IL-1Ra-
mediated anti-inflammatory action which is attributed to
ACS by several authors [8, 11, 13], although IL-1Ra con-
centrations in ACS were not determined in the present
study. Another potential pathway may be the supple-
mentation of growth factors, such as IGF-1 and TGF-β,which are supposed to be increased in equine ACS
[12, 16, 21]. IGF-1 is known to be decreased for approxi-
mately 2 weeks in experimentally induced tendinopathy
and a beneficial bolstering effect of exogenous IGF-1 on
low endogenous IGF-1 production during the early re-
pair phase of tendinopathy has been hypothesized [34].
ACS has been shown to display significant effects on the
endogenous expression of growth factors potentially via
auto- and paracrine pathways [16]. It remains unclear why
the significant differences between groups with regard to
%T-lesion and TES were not consistent until the end of
the observation period despite tendencies to significance.
This may be attributed to a time-limited effect of ACS
(see above). Ultrasonographic tissue characterization has
been established in recent years as a more precise alterna-
tive to B-mode ultrasonography to monitor the process of
tendon healing [37, 38], particularly if only a probe with a
relatively low resolution is available as in the present
study.
With regard to histologic scores, a difference between
groups was seen at day 36. Here, cell nuclei were flat-
tened in the ACS group compared to controls, which is
suggestive of decreased tenocyte proliferation in the late
proliferative phase (4–45 days) [1, 23, 34, 35] as a re-
sponse to the ACS injection. In agreement with this, it
has been shown that tendon fibroblasts with a spindle-
shaped nucleus have reduced apoptotic and proliferative
indices, as demonstrated in human patellar tendons [35].
A consequence might be a decreased cellular production
of inelastic collagen type III, which has been described
to peak between 3 to 6 weeks after injury in equine ex-
perimental studies [34, 51]. However, immunohisto-
chemistry in the present study revealed no difference of
collagen type III expression between groups which might
be due to considerable variations of different types of
collagen between individual lesions, as described for nat-
urally developed lesions in horses [1, 44].
The more favourable development of collagen type I
expression in the ACS group between days 36 and 190
indicates qualitative improvement [34, 51], such as in-
creased tensile strength of the repair tissue in the re-
modelling or maturation phase (45–120 days) [36],
which is potentially caused by the mechanisms men-
tioned, i.e. an IL-1Ra-mediated anti-inflammatory mech-
anism or the supplementation of growth factors, such as
IGF-1 and TGF-β. Collagen type I was seen to be ele-
vated for 6 months after injury in equine experimental
studies [34]. This rather reflects the progress in control
tendons of the present study and correlates with previ-
ous findings in naturally injured equine tendons [44]. In
contrast to an experimental Achilles tendinopathy model
using ACS-treated rats [22], no difference in collagen
type I expression was detected between groups in the
present study. However, rat Achilles tendons were
Geburek et al. Stem Cell Research & Therapy  (2015) 6:126 Page 12 of 14treated three times at 24-hour intervals with the first in-
jection 24 hours after induction of the lesion, i.e. in the
acute inflammatory phase of tendon healing. By contrast,
tendons in the present study received only a single intra-
lesional injection of ACS up to 14 days after the onset of
clinical symptoms, i.e. mostly at the end of or even after
the acute inflammatory phase. In the latter investigation,
real-time quantitative polymerase chain reaction was
used, which allows quantification of mRNA transcription
of different collagen types, provided that enough tissue
is available. Cytokines such as IL-1Ra and the growth
factors IGF-1 and TGF-β have a short half-life and they
may be degraded and consumed within a short time
period after exogenous application [14–16]. Neverthe-
less, tendon healing may not only be enhanced by direct
binding of cytokines and growth factors to cell surface
receptors, but also due to indirect effects by stimulation
of endogenous production of growth factors [13, 16, 52].
Therefore, the effect of ACS is potentially enhanced by
several consecutive injections [22], as reported anec-
dotally to be common in equine practice and as recom-
mended for the treatment of joint pathology [13]. A
single ACS injection was chosen to determine the effect
of a low dose as a basis for research because, to date,
neither dose-dependent in vivo studies nor a consensus
on the treatment protocol are available for blood prod-
ucts such as ACS. Another aim was to keep the number
of factors influencing outcome, such as repeated needle
puncture of tendons, as low as possible.
The increase in collagen I expression after ACS injec-
tion in an experimental rat study did not coincide with
an improved maximum load to failure, despite leading to
an improvement in tendon stiffness during biomechan-
ical testing [22]. Although biomechanical testing is
regarded as the method of choice, it could not be ac-
complished in the present study due to the inclusion of
client-owned horses. In general, the degree of lameness
and, to a limited extent, the echo pattern of the injured
tendon reflect biomechanical properties. These parame-
ters, however, did not significantly differ between groups
in the present study at the end of the observation period.
Due to the reduced group size, differences in long-term
recurrence rate after return of the horses to full exercise
could not be calculated statistically.
Conclusions
This clinical trial in horses with acute tendinopathies of
the SDFT shows that a single intralesional ACS injection
contributes to significant reduction of lameness within
10 days and to improvement of ultrasonographic param-
eters of repair tissue between 11 and 23 weeks after
treatment. Intralesional ACS treatment potentially de-
creases proliferation of tenocytes 5 weeks after treatment
and increases their differentiation, as demonstrated byan elevated collagen type I expression in the remodelling
phase. Repeated ACS injections should be considered to
enhance positive effects. Future controlled long-term in-
vestigations should be performed in a larger number of
horses to determine the effect on recurrence rate.
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